Tuesday, February 28, 2012

Family tree may clarify death risk for inherited heart rhythm disorders

February 28, 2012 Study Highlights:By reconstructing family trees dating back to 1811, Dutch researchers have estimated the death risk for people with inherited abnormal heart rhythms.Doctors can use this information to determine when to screen and treat patients with these syndromes and their relatives.EMBARGOED UNTIL 3 p.m. CT/4 p.m. ET, Tuesday, Feb. 28DALLAS, Feb. 28, 2012

American Heart Association Comment: FDA announces safety changes on labeling for some statins

The United States Food and Drug Administration (FDA) announced it is revising safety information on the labels of some statins (cholesterol lowering drugs). Statins are a class of drugs that work in the liver to prevent the formation of cholesterol.   They are most effective at lowering the LDL (bad) cholesterol, but also have modest effects on lowering triglycerides (blood fats) and raising HDL (good) cholesterol.   High cholesterol is a risk factor for cardiovascular disease and stroke.  The FDA changes to the statin labels include:Revising the drug labels to remove the need for routine periodic monitoring of liver enzymes in patients taking statins.    Including labeling information about some patients experiencing memory loss and confusion.  Warning healthcare professionals and patients of the potential risk of increased blood sugar levels and of being diagnosed with type 2 diabetes mellitus.The announcement also alerts health care professionals to new recommendations in the lovastatin label, including drug interactions like those with drugs used to treat HIV (protease inhibitors). “The FDA’s announcement on the label changes does not question the benefit of statins to lowering cholesterol, but it does provide patients and healthcare providers the most current information about the safe use of statins,” said Gordon F. Tomaselli, M.D., president of the American Heart Association.  “Not surprising, but important for practitioners with regard to routine liver function test screening, which is no longer recommended, but should be done at baseline and for symptoms.  This will change practice although I will remain vigilant in people with prior history of liver disease, people who drink or who are taking multiple drugs metabolized by the liver.   Also, the contraindications of use of in particular anti-HIV drugs with Mevacor (lovastatin) are important to reemphasize as is the known but infrequent increase in blood sugar in patients taking statins.” Tomaselli says “while we recommend healthy people focus on prevention using lifestyle changes rather than drug therapy whenever possible, for some people, lifestyle changes aren’t enough. As with all therapies, the decision to use statins for primary or secondary prevention must include careful consideration of the risks and benefits, side-effects and cost.   Working with your healthcare provider to be sure you’re doing what you need to do to stay healthy is the best approach.” For more information on lowering your risk factors for heart disease and stroke, visit www.heart.org.###Additional resources:FDA news release Cholesterol lowering drugs information ADV12-1002 The American Heart Association/American Stroke Association receives funding mostly from individuals. Foundations and corporations donate as well, and fund specific programs and events. Strict policies are enforced to prevent these relationships from influencing the association’s science content. Financial information for the American Heart Association, including a list of contributions from pharmaceutical companies and device manufacturers, is available at www.heart.org/corporatefunding. For media requests:Tagni McRae: 214-706-1383; tagni.mcrae

Monday, February 27, 2012

What Are Your Stomach Pain Symptoms Trying to Tell You?

By Sharon Gillson, About.com Guide   February 26, 2012

My BioHeadlinesForumRSS

Follow me on:

FacebookTwitter

If you are suffering from stomach pain, you need to find the cause before you can start a treatment. Here are a few of the conditions that can cause stomach pain.

Heartburn Related Resources:

Meal Planning Tips for Preventing Heartburn Dining Out Without Heartburn Foods with Little Risk of Causing Heartburn Preventing Nighttime Heartburn

Peptic Ulcer Related Resources

Surgery for Peptic Ulcers Complications of Peptic Ulcers Peptic Ulcer Warning Signs Peptic Ulcers in Children

Gallstone Related Resources:

What is the Gallbladder? What are Gallstones? What Increases the Risk of Developing Gallstones Diagnosing GallstonesComments (0)See All PostsSharePrevNextCommentsNo comments yet. Leave a CommentLeave a CommentName

Recent Study Highlights Risk of Haloperidol (Haldol) for Persons with Dementia

A recent study published in the online journal BMJ outlines research on antipsychotic medications and their use in people with Alzheimer's and other dementias.

Antipsychotics are a specific type of psychotropic medication that are often used to help control some of the challenging behaviors that people with dementia experience. The initial approach to behaviors should always be to use behavior modification strategies and attempt to determine the causes behind the behaviors, since we know that most behavior has meaning. However, medications are also prescribed when these non-drug approaches are ineffective.

This recent study reviewed more than 75,000 people in the United States who had been prescribed antipsychotic medications in nursing homes from 2001-2005. (Data from people in nursing homes is fairly easy to collect; nursing homes are required to report data regularly since they receive funding from Medicare and Medicaid.) Researchers tracked the doses and the type of antipsychotic medication, as well as the mortality rates of those receiving the medications.

The results show that those receiving a specific type of antipsychotic medication called Haldol (haloperidol) have a significantly increased risk of death, especially shortly after treatment is started, compared to other types of antipsychotic medications.

Haldol is a typical antipsychotic, which places it in a classification of an older medication that often has more risks. Several of the other antipsychotic medications they reviewed were of the atypical class, which is a newer kind of antipsychotic medication that usually has less side effects than the typical ones.

A couple of thoughts about this study:

Having been in the nursing home industry for several years, I can say with confidence that good facilities monitor the use of antipsychotics very closely. These medications have to be periodically reduced, and should not be used without trying non-drug interventions first.When research shows a clear risk, as it does here, it highlights your role as an advocate for a family member or friend with dementia. If your loved one is on an antipsychotic, particularly haloperidol, you might consider asking questions about why that drug was chosen, if another medication could be used instead, or if the medication can be decreased or stopped.

Living Well with GERD: Watch What You Eat

By Sharon Gillson, About.com Guide   February 26, 2012

My BioHeadlinesForumRSS

Follow me on:

FacebookTwitter

One of the leading triggers of heartburn is the food we eat. Since we all have to eat, we need ways to prevent food from causing heartburn. This involves making wise food choices.

There are foods you should avoid if you suffer from heartburn. Along with avoiding certain foods if they trigger your heartburn, there are some meal planning tips to have you avoid heartburn.

Everyone is different; what may be a heartburn trigger for someone else may be safe for you to eat, and what others can eat with no problems will cause you a lot of discomfort. For this reason it is important that you keep a food diary to determine which foods are problematic for you.

Related resources:

Foods with little risk of causing heartburn Heartburn friendly recipes Dining out without heartburn Heartburn-free picnics Heartburn-free school lunches Comments (0)See All PostsSharePrevNextCommentsNo comments yet. Leave a CommentLeave a CommentName

Getting Quick Heartburn Relief

By Sharon Gillson, About.com Guide   February 26, 2012

My BioHeadlinesForumRSS

Follow me on:

FacebookTwitter

Whether you suffer from heartburn once a month or once a week, there are times when you want quick relief from that burning sensation. Here are a few quick relief options:

Chew gumBaking sodaApple cider vinegarAntacidsComments (2)See All PostsSharePrevNextLeave a CommentCommentsMarch 16, 2011 at 12:18 am(1) Gert says:

I personally chew sugarless gum and take Maalox Advanced maximum strength. Four teaspoonsful work like a charm.

I chew fruit sensational gum.

Sincerely.

Gert McMillian

October 30, 2011 at 6:45 pm(2) Rory says:

Soda just make it worst
I use to drink milk

Leave a CommentLeave a CommentName

Saturday, February 25, 2012

What to do for stings


For Stings
Signs & Symptoms
Quick, sharp pain.
Swelling, itching, and redness at the sting site. These can occur beyond the sting site.
Raised bump (with or without pus).
Signs of a severe allergic reaction.


Causes
Insect stings.
Marine animals that sting include jellyfish, Portuguese Man-of-War, and sea nettles.


Treatment
Self-care treats mild reactions to stings. A severe allergic reaction needs immediate care. Symptoms of a severe allergic reaction usually happen soon after or within an hour of the sting. Persons with a severe allergic reaction to a sting in the past should carry an emergency kit, prescribed by a doctor. A medical alert tag should be worn to let others know of the allergy. Persons who have had severe reactions to bee or wasp stings should ask their doctors about allergy shots.

What to do for bites


Bites

For Bites
Signs & Symptoms
Swelling. Redness. Pain. Itching.
Bleeding.
Tissue loss, if the wound is severe.
Skin rash. With Lyme disease, a red bull's eye rash with a white center around the bite occurs. Fatigue, fever, and joint pain may also occur.
Lockjaw. This is a painful, persistent stiffness of the jaw due to a toxin. Tetanus shots can prevent this. (See Immunization Schedule.)
Allergic reaction, such as with insect bites. (See Signs & Symptoms of Allergies.)

Causes
Dog, cat, and human bites are the most common animal bites in the U.S.
Black widow and brown recluse spider bites can cause severe reactions.
Deer tick bites can cause Lyme disease, a bacterial infection.
Less common, but more dangerous, are bites from skunks, raccoons, bats, and other animals that live in the wild. These animals can have rabies. This is a serious viral infection. It can be fatal. Most house pets are vaccinated for rabies. It's unlikely they carry the virus.
Deer tick on scalp.
Mosquito bites can cause West Nile virus if the mosquito is infected with it.
Snake bites can be fatal if the bite is from a poisonous snake (e.g., rattlesnakes, cotton mouths, copperheads, and coral snakes).
Shark bites are a potential problem when swimming in shark-infested waters.



Treatment
Self-care can be used for dog and cat bites that cause scratches on the skin and for insect bites that do not cause a severe allergic reaction. All human bites that break the skin should be checked by a doctor due to the high risk for infection. A series of rabies shots can prevent the spread of rabies to humans. The shots should begin soon after a bite from an infected animal. Antivenom can be given for poisonous snake bites at

Wednesday, February 22, 2012

New Guidelines Seek to Prevent Sudden Death in Young Athletes

WEDNESDAY, Feb. 22 (HealthDay News) --New guidelines outlining the causes and prevention of sudden death among athletes were released this week by the National Athletic Trainer's Association (NATA) in the United States.

"These guidelines were developed for any level of sports participation, and to truly help save a life," NATA President Marjorie Albohm said in an association news release. "It is also critical that a school, team or league's medical professionals have an emergency action plan in place. In the event that an injury occurs, every minute counts when it comes to appropriate care and transport of the athlete."

"While collegiate and professional teams have athletic trainers on staff to prevent and treat injuries, only 42 percent of high schools have access to our members," Albohm noted. "Legislation is improving, though, with 35 states and Washington, D.C., having passed youth sports safety laws. And the NFL just mandated new guidelines requiring athletic trainers in booths during games to watch for hard hits and concussions."

The new position statement includes many recommendations for preventing sudden death among athletes. Here are some of the highlights:

An athlete's chances of survival are much greater if there is an established, site-specific emergency plan.Recognition of the type of problem is key to treatment. Sudden cardiac arrest should be suspected in any athlete who has collapsed and is unresponsive.Public access to early defibrillation is critical. The time between when an athlete collapses and receives the first shock from an automated external defibrillator should be less than three to five minutes.If a serious brain injury is suspected in an unresponsive athlete, medical staff must be prepared to transport the athlete to a health-care facility, while ensuring adequate ventilation and elevating the head to help decrease intracranial pressure.In cases of suspected heatstroke, the athlete's core temperature must be determined soon after collapse to ensure accurate and immediate assessment.Ensure athletes with asthma are properly educated about their condition and how to recognize good or bad breathing days. A structured warm-up program may decrease their risk of an asthma attack or their reliance on asthma medications.

The position statement appears in the February issue of the Journal of Athletic Training.

More information

Washington University has more on preventing sudden death in young athletes.

Support for Tougher Liquor Laws Rises When Booze, Crime Linked

WEDNESDAY, Feb. 22 (HealthDay News) -- News coverage of alcohol's role in violent crime and fatal accidents may persuade the public to give stronger support to alcohol-control laws, new research suggests.

It is estimated that drinking is involved in nearly one-third of deaths from accidents and violent crime. Most news reports of such cases, however, make no mention of alcohol, according to the authors of the study, published in the March issue of the Journal of Studies on Alcohol and Drugs.

"People have some awareness of the social cost that alcohol can have," study author Michael D. Slater, of Ohio State University, in Columbus, said in a journal news release. "But only a small fraction of news stories on violent crime and nonmotor-vehicle accidents acknowledge the contributing role of alcohol."

This means that many people don't realize how often alcohol plays a role in violence and accidents that don't occur on the roads. This lack of awareness may dampen public support for alcohol-control laws such as strict enforcement of underage drinking rules or bans on serving alcohol to drunk customers, Slater said.

In the study, Slater and his colleagues surveyed 789 adults and found that they were more likely to support alcohol-control laws after they read media stories about violent crime, vehicle crashes and other accidents involving alcohol.

"I think this buttresses the idea that media coverage does matter," Slater said. "Alcohol, as a public-health issue, is not as front and center as it might be if there were more news coverage."

In areas that already have alcohol-control laws, public support is still important because local resources are needed to enforce those laws, he noted. Local authorities should mention any role of alcohol when giving details about crimes and accidents to the media, Slater added.

More information

The U.S. Centers for Disease Control and Prevention offers an overview of alcohol and public health.

American Heart Association launches free-access online journal

February 21, 2012 Initial studies focus on stroke, peripheral artery disease, heart failure and diabetesNews Highlights:Among findings posted in the inaugural publication of the American Heart Association’s online-only, free-access scientific journal:The NIH Stroke Scale accurately identifies patients with the highest risk of death in the first month after stroke.Aspirin works as well as more expensive drugs in combination with a walking program to treat blocked leg arteries.Heart failure patients do better when they receive several evidence-based treatments at once.Kidney problems signal the highest death risk for people with type 2 diabetes.EMBARGOED UNTIL 3 p.m. CT/4 p.m. ET, Tuesday, Feb. 21DALLAS, Feb. 21, 2012

Raw Milk Causes Most Illness From Dairy Products: CDC

TUESDAY, Feb. 21 (HealthDay News) -- Raw, or unpasteurized, milk causes 150 times more dairy product-related disease outbreaks than pasteurized milk. And states where the sale of raw milk is legal have twice as many outbreaks as states where it is illegal, according to a new U.S. Centers for Disease Control and Prevention study.

"This study shows an association between state laws and the number of outbreaks and illnesses from raw milk products," Dr. Robert Tauxe, deputy director of CDC's division of foodborne, waterborne and environmental diseases, said in an agency news release.

The 13-year review looked at more than 120 dairy product-related outbreaks that occurred in 30 states between 1993 and 2006. The outbreaks caused more than 4,400 illnesses, 239 hospitalizations and three deaths.

Raw milk products -- including cheese and yogurt -- caused 73 of the outbreaks (60 percent) and most of the 239 hospitalizations.

Some people mistakenly believe that raw milk is a healthier alternative to pasteurized milk, according to the U.S. Food and Drug Administration. Its website debunks the notion that raw milk is less likely than pasteurized milk to cause lactose intolerance, an inability to digest milk products.

Unless milk is pasteurized -- heated to kill harmful bacteria -- bacteria can accumulate in collected milk, multiply and cause illness, the researchers said.

The study found that 13 percent of patients in raw milk outbreaks were hospitalized, compared with 1 percent of those made ill by pasteurized milk products. This may be because raw milk outbreaks were all caused by bacteria, such as E. coli O157, that tend to provoke more severe illness, according to the study.

On the other hand, pasteurized milk and cheese outbreaks were often caused by milder infections, such as norovirus and Staphylococcus aureus.

Fifty-five of the outbreaks reviewed occurred in the 21 states where it was legal to sell raw milk at the time, the CDC found.

Young people were much more likely to get sick from raw milk products than pasteurized items. Where ages were available, people younger than age 20 accounted for 60 percent of patients in raw milk outbreaks, compared with 23 percent of patients in pasteurized milk outbreaks.

During the study period, about 2.7 trillion pounds of milk was produced in the United States. By comparing that amount to the estimated 27 billion pounds (1 percent) consumed raw, the study authors determined that raw milk products cause 150 times more outbreaks than pasteurized milk.

The study appears Feb. 21 in the journal Emerging Infectious Diseases, published by the CDC.

It's impossible for consumers to tell if raw milk is safe to drink by looking at, smelling, or tasting it, the CDC said.

"Restricting the sale of raw milk products is likely to reduce the number of outbreaks and can help keep people healthier. The states that allow sale of raw milk will probably continue to see outbreaks in the future," Tauxe said.

Study co-author Barbara Mahon, deputy chief of the CDC's Enteric Diseases Epidemiology Branch, said in the news release: "While some people think that raw milk has more health benefits than pasteurized milk, this study shows that raw milk has great risks, especially for children, who experience more severe illnesses if they get sick.

"Parents who have lived through the experience of watching their child fight for their life after drinking raw milk now say that it's just not worth the risk," she added.

More information

The U.S. Food and Drug Administration has more about raw milk.

Monday, February 20, 2012

Some states denying immunity for the community


While we at ACSH have long been working to promote increased immunization rates, lawmakers in many states are contemplating a move in the opposite direction. Seven states are currently considering bills that would make it easier for parents to have their kids skip important childhood vaccinations.

Currently, all states except for West Virginia, Mississippi, and Washington D.C. allow parents to exempt their children from vaccines that are required by schools due to religious beliefs. Additionally, 19 states allow “philosophical exemptions” for required childhood vaccinations. Now, West Virginia and Mississippi, in addition to five more states, are considering joining the ranks of those that permit such philosophical exemptions.

As Diane Peterson, associate director at the Immunization Action Coalition, says, “That’s not a move in the right direction.” ACSH's Dr. Elizabeth Whelan wholeheartedly agrees. “If these bills pass, parents will keep their kids from getting vaccinated for whatever reasons they choose,” she says. “This will put not only their own children, but also the rest of the school population, at risk of diseases that are entirely preventable and that can be dangerous for young people. There need to be consequences for people who refuse to be vaccinated.”

Organically confused


When many people see a label that says “organic,” they tend to interpret this as a clear sign that the food is both safer and more nutritious than a conventional product. But an organic label doesn’t guarantee safety or greater nutritional value, as the results of a new Dartmouth study emphasize. The study focused on organic brown rice syrup — a sweetener found in some foods, including certain infant formulas, cereal and energy bars, and high-energy foods consumed by athletes.

The researchers purchased these food products —  some of which contained organic brown rice syrup —  and analyzed them for levels of arsenic. The results, published in the journal Environmental Health Perspectives, may come as a surprise to those who consider “organic” to be superior products: The foods that contained organic brown rice syrup actually had significantly higher levels of arsenic than those that did not use the syrup. In fact, the two infant formulas that listed organic brown rice syrup as the primary ingredient contained levels of arsenic over 20 times higher than the other infant formulas.

Brown rice syrup may be particularly susceptible to arsenic contamination since rice easily absorbs this chemical, which can be found in groundwater. Yet ACSH's Dr. Elizabeth Whelan points out that even the levels found in the samples tested in this study should not concern the average consumer.

ACSH's Dr. Josh Bloom remarks that the irony of this story is “the hypocrisy of the organic food industry. They add a sweetener that sounds healthy because it’s ‘organic,’ but in reality it contains more arsenic than regular sugar does.”

“People keep forgetting that organic labeling has nothing at all to do with nutritional value or safety,” ACSH's Dr. Ruth Kava points out. “Yet consumers continue to think that if it’s organic, there can’t be anything wrong with it.”

Don’t accept any counterfeit pills


It seems like a problem that would exist only in the developing world — counterfeit drugs making it into the mainstream market. But American consumers are becoming increasingly concerned about counterfeit medications ending up in their own pharmacies: The FDA has confirmed that a fake version of the cancer drug Avastin was sold to at least 19 doctors and clinics. Fortunately, although the counterfeit drug did not contain any actual Avastin, there have been no reports of harm. But in the wake of several other counterfeiting incidents in the U.S., including the weight-loss drug Alli and the cholesterol-lowering Lipitor, it appears that fake drugs are indeed a reality even in our country.

“We have no way of knowing what counterfeit medicines contain, or whether they were produced in carefully controlled conditions,” says ACSH’s Dr. Ruth Kava. “In addition to having no efficacy, they could also contain contaminants.”

ACSH’s Dr. Josh Bloom says that the biggest concern is with IV drugs. “If these contain any contaminants, such as bacteria or particulate matter, they will go straight into the bloodstream, which could do a lot of harm,” he notes. “Although counterfeit pills can be dangerous, the potential for harm is greater with injectables.”

While some counterfeit drugs are infiltrating the American market, the developing world is certainly harder hit than developed regions; in Asia and Latin America, up to 30 percent of medications sold are fake, as opposed to just 1 percent in the U.S. and other developed countries. Indeed, out of the 1,700 counterfeiting incidents reported by pharmaceutical companies last year, only 6 percent occurred in the U.S.

Overall, ACSH's Dr. Elizabeth Whelan would like to reassure the public that counterfeit drugs are extremely rare in the U.S. “You should by no means be afraid to go to the pharmacy and pick up a prescription,” she says. To read more about this problem and what can be done to help prevent the spread of potentially dangerous fakes, check out ACSH’s 2009 publication, Counterfeit Drugs: Coming to a Pharmacy Near You.

Lack of sex disparity in cardiovascular testing after coronary computerized tomographic angiography.

 1.19 to 1.91), while male sex, age, race, and Thrombolysis in Myocardial Infarction (TIMI) risk score were not. Conclusions:  Male patients with potential ACS who receive a coronary CTA as a part of their ED evaluation were no more likely than female patients to receive further testing within 30 days.



View the Original article

Sunday, February 19, 2012

Post-stroke language impairment adds thousands to medical costs

February 16, 2012 Study Highlights:Stroke-related language impairment, a condition called aphasia, costs an average $1,703 per patient more than the cost of stroke alone one year after stroke.Aphasia patients tend to be older, have had more severe strokes and longer stays in healthcare facilities.Annually, about 100,000 people who suffer a stroke will be left with language deficits due to aphasia.Embargoed until 3pm Ct/4pm ET DALLAS, Feb. 16, 2012 — Stroke-related language impairment adds about $1,703 per patient to medical costs the first year after stroke, according to research reported in Stroke: Journal of the American Heart Association. Researchers retrospectively examined the records of 3,200 South Carolina Medicare patients who had ischemic strokes in 2004 and found:Twelve percent (398 patients) had aphasia or language impairment.Medicare payments for those with aphasia averaged $20,734 per patient vs. $18,683 for those without it — an 8.5 percent increase.Aphasia patients were older and had more severe strokes.Aphasia patients stayed in healthcare facilities 6.5 percent longer and had higher rates of illness and death.“These findings are important because dramatic changes are occurring in healthcare reimbursement, specifically imposed caps on Medicare reimbursement for outpatient speech language pathology and physical therapy,” said Charles Ellis Jr., Ph.D., lead author and associate professor of Health Sciences and Research at the Medical University of South Carolina in Charleston. “Although the current reimbursement cap is $1,870 for these therapies, the financial burden of the cap remains a major limiting factor to access long-term rehabilitation for patients with persisting aphasia.” Annually, about 100,000 people who suffer a stroke will be left with language deficits due to aphasia. Co-authors are: Annie N. Simpson, M.Sc.; Heather Bonilha, Ph.D.; Patrick D. Mauldin, Ph.D.; and Kit N. Simpson, Dr.Ph. Author disclosures are on the manuscript.### Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www. heart.org/corporatefunding. NR12 – 1030 (Stroke/Ellis) Additional resources and multimedia is available on the right column of the release:http://newsroom.heart.org/pr/aha/_prv-post-stroke-language-impairment-228952.aspx For Media Inquiries, please call: (214) 706-1173Tagni McRae: (214) 706-1383; tagni.mcrae

Peripheral artery disease undertreated, understudied in women

American Heart Association Scientific Statement February 15, 2012 Statement Highlights:Peripheral artery disease, or PAD, can increase the risk of heart attack or stroke, yet is often unrecognized and untreated in women.Healthcare providers should educate and test women at risk for PAD, which is characterized by narrowing blood vessels, usually in the legs, feet, and arms.Public awareness campaigns such as the American Heart Association’s Go Red For Women can be effective in spreading knowledge about PAD.Embargoed for 3pm CT/4pm ET DALLAS, Feb. 15, 2012

All Americans Will Bear the Pain of Prevention Fund Cut, Says Nancy Brown, American Heart Association CEO

February 17, 2012 Washington, D.C., Feb. 17, 2012 — American Heart Association CEO Nancy Brown issued the following comments on the payroll tax extension legislation, approved today by Congress, which includes a 30 percent cut to the Prevention and Public Health Fund:  “By diverting crucial dollars away from the Prevention and Public Health Fund to support the payroll tax extension, Congress has taken an action that could adversely affect the health of all Americans. In the next 20 years, 40 percent of the U.S. population will have some form of cardiovascular disease. By 2030, the combined medical costs and lost productivity due to these diseases is projected to triple to $1 trillion, resulting in a devastating impact on the health of Americans and the U.S. economy. One of the best ways to avert this crisis is to invest money now in programs that propel the use of widely recognized prevention measures, such as not smoking, maintaining a healthy body weight and exercising. This fund provides support for programs that can help Americans adopt these healthy habits, and ultimately drive down our nation’s rising healthcare costs. Investing in prevention will help keep our economy strong and help Americans get healthy. The American Heart Association remains a strong supporter of the Prevention and Public Health Fund, and we urge Congress and the administration to protect it from future cuts.”   ###Contact:  Retha Sherrod, (202) 785-7929retha.sherrod

Good Football Helmet Fit Key to Preventing Brain Injuries

FRIDAY, Feb. 17 (HealthDay News) -- While football helmets don't prevent concussions, good helmet fit might help reduce loss of consciousness that can follow a blow to the head, a new study finds.

Expensive, high-tech helmets with air-lining systems aren't much better than vintage "leatherheads" for preventing concussions, the researchers said.

"The occurrence of concussion has been constant for the past 30 years: whether it was a leather helmet, whether it was a plastic helmet with web suspension, whether it was a plastic helmet with foam, or one with the new combination air cells and padding," said study author Dr. Joseph Torg, an adjunct professor of orthopedic surgery at Temple University in Philadelphia.

The researchers looked at data from the U.S. National High School Sports-Related Injury Surveillance System from 2005 to 2009. Of the nearly 1,400 kids who sustained a concussion, 44 lost consciousness and 267 experienced amnesia.

Injury reports addressed helmet fit, type of inner-helmet padding and whether the helmet was new or reconditioned.

"Youngsters who had a concussion, if the helmet fit, they had 82 percent less chance of loss of consciousness," Torg said. "Helmets -- and advanced helmet technology -- do not prevent against concussions or the severe intracranial injuries of hemorrhage

How useful are the Heart Foundation risk criteria for assessment of emergency department patients with chest pain?

wh.org.au

Publication HistoryArticle first published online: 14 FEB 2012Accepted 30 December 2011 SEARCH Search Scope All contentPublication titlesIn this journalIn this issue Search String Advanced >Saved Searches > SEARCH BY CITATION Volume: Issue: Page: ARTICLE TOOLSGet PDF (152K)Save to My ProfileE-mail Link to this ArticleExport Citation for this ArticleGet Citation AlertsRequest Permissions AbstractArticleReferencesCited By View Full Article (HTML) Get PDF (152K) Keywords:acute coronary syndrome;chest pain;risk stratificationAbstract

Objective: To investigate the prognostic utility of Heart Foundation (Australia) risk stratification table in an ED chest pain population.

Methods: A planned sub‐study of a prospective observational study of adult patients with potentially cardiac chest pain who underwent evaluation for acute coronary syndrome (ACS) was conducted. Data collected included demographical, clinical, ECG, biomarker and outcome data. Outcome of interest was diagnostic utility of the classification system for ACS or myocardial infarction (MI) at index presentation and major adverse cardiac events (MACE) within 7 and 30 days. MACE included death, cardiac arrest, revascularization, cardiogenic shock, arrhythmia and prevalent (cause of presentation) and incident (occurring within the follow‐up period) MI. Analysis was by descriptive and receiver–operator curve analyses.

Results: Seven hundred and sixty‐eight patients were studied; 109 had MI (14.2%, 95% confidence interval

Fatal disconnection of a ventricular assist device in an out-of-hospital setting

Twitter What's this?

This Article Extract Full text PDF All Versions of this Article: emj.2010.098525v1 29/3/247 most recent Services Email this link to a friend Alert me when this article is cited Alert me if a correction is posted Alert me when eletters are published Article Usage Statistics Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Add article to my folders Download to citation manager Request permissions Add to portfolio Responses Submit a response No responses published Citing articles Load citing article information Citing articles via Web of Science Citing articles via Scopus Google Scholar Articles by Bischof, D. Articles by Hofer, C. K. Search for related content PubMed PubMed citation Articles by Bischof, D. Articles by Hofer, C. K. Related Content Resuscitation Cardiomyopathy Mechanical ventilation Mechanical ventilation Load related web page information Social bookmarking

Body temperature of trauma patients on admission to hospital: a comparison of anaesthetised and non-anaesthetised patients

Twitter What's this?

This Article Abstract Full text PDF Web Only Data All Versions of this Article: emj.2009.086967v1 29/3/239 most recent Services Email this link to a friend Alert me when this article is cited Alert me if a correction is posted Alert me when eletters are published Article Usage Statistics Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Add article to my folders Download to citation manager Request permissions Add to portfolio Responses Submit a response No responses published Citing articles Load citing article information Citing articles via Web of Science Citing articles via Scopus Google Scholar Articles by Langhelle, A. Articles by Davies, G. Search for related content PubMed PubMed citation Articles by Langhelle, A. Articles by Davies, G. Related Content Other anaesthesia Load related web page information Social bookmarking

Interhospital variation in the RATPAC Trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers)

2243) and economic analysis comparing diagnostic assessment using the panel to standard care for patients with acute chest pain due to suspected myocardial infarction at six hospitals. The difference in the proportion of patients successfully discharged (primary outcome) and mean costs per patient between the participating hospitals was compared.

Results Point-of-care assessment led to a higher proportion of successful discharges in four hospitals, a lower proportion in one and was equivocal in another. The OR (95% CI) for the primary outcome varied from 0.12 (0.01 to 1.03) to 11.07 (6.23 to 19.66) with significant heterogeneity between the centres (p<0.001). The mean cost per patient for the intervention group ranged from being

Saturday, February 18, 2012

Antibiotics for most sinus infections are anti-effective


Sinus infections are miserable. Anyone suffering from one wants relief as soon as possible. The tricky thing is, the overwhelming majority of such infections are caused by viruses; only about 2 percent of sinus infections are bacterial. Since viral infections do not respond to antibiotics, having your doctor prescribe an antibiotic is unlikely to help. And a new study just published in the Journal of the American Medical Association confirms this: Sinus infection patients treated with the antibiotic amoxicillin were no better off than those given a placebo pill.

You’ve got to: Move it


The basic idea is conventional wisdom: Children who spend more time physically active than their sedentary peers will generally be healthier. Now a new study in the current Journal of the American Medical Association has refined this common understanding, looking specifically at the amount of time spent physically active and sedentary as it relates to certain risk factors in otherwise healthy children. The findings suggest that the length of time a child spends being physically active, regardless of sedentary time, is key to improved heart and metabolic health.

Friday, February 17, 2012

Just when you thought the flu season flew by


Though we’re already halfway through February, this year’s influenza season is just starting to pick up steam. According to data from the Centers for Disease Control and Prevention (CDC), this is the slowest start to the flu season in almost thirty years. Normally the virus prevails in January, though it can hit as early as October and can continue as late as May.
 
Areas in the central and northwestern U.S. are only now reporting an uptick in flu-like illnesses, while California is already experiencing widespread flu activity. As Dr. Richard Zimmerman, a professor of family medicine at the University of Pittsburgh School of Medicine, explains, “It’s fairly common for the west to precede the east” as far as the spread of the virus is concerned. Dr. Zimmerman also reminds everyone that “this is really the last chance to get vaccinated,” since it takes about one to two weeks for the vaccine to be effective.
 
ACSH seconds Dr. Zimmerman’s recommendation and encourages folks to visit their local pharmacy or healthcare professional to get immunized while it’s not too late!

Toothbrush Can Chip Teeth and Cause Choking

Two models of the Spinbrush are shown here. To help prevent injury, inspect the Spinbrush for damage or loose bristles before each use, and always supervise children and adults who may need assistance when using it.

Thursday, February 16, 2012

Diagnostic accuracy of nitroglycerine as a 'test of treatment' for cardiac chest pain: a systematic review

2 contingency tables. Five eligible studies were found, all in the acute setting (although one paper collected its data in the follow-up setting, all patients had acute presentations). The sensitivity ranged from 35% to 92% and the specificity from 12% to 63%. However, in all but one paper the Youden indices were close to zero suggesting that the response to nitroglycerine is not useful as a diagnostic test. The combined sensitivity was 0.52 (95% CI 0.48 to 0.56) and combined specificity was 0.49 (95% CI 0.46 to 0.52). The diagnostic OR from the combined studies was 1.2 (95% CI 0.97 to 1.5), which is not significantly different from 1. In the acute setting, nitroglycerine is not a reliable test of treatment for use in the diagnosis of coronary artery disease. However, further studies are needed to determine the diagnostic accuracy of nitroglycerine for recurrent exertional chest pain.

Cardiac care acute coronary syndrome thrombo-embolic disease diagnosis Footnotes Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.



View the Original article

Wednesday, February 15, 2012

Quality control for biosimilars


Biosimilars — the generic versions of biological drugs — are considerably more difficult to produce than regular drugs. Now, a new draft guidance issued last week by the FDA aims to more precisely define the steps biopharmaceutical companies must follow to navigate the approval process and to delineate the quality standards for reproducing such medications. Although the Affordable Care Act specified that the FDA must issue such a guidance, no company has yet applied for approval.

While standard drugs are generally small molecules that can be uniformly reproduced by any given manufacturer, biosimilar drugs cannot be so exactly replicated. These drugs are usually larger, more complex compounds that must undergo an extensive manufacturing process — one that will undoubtedly create some variation among the final products.

That biological drugs are so susceptible to variation makes it especially important to ensure that generic companies are making a version of the drug that is sufficiently similar to the approved brand-name product. ACSH's Dr. Josh Bloom explains: “Conventional drugs, like Lipitor, are single compounds that are generally easy to manufacture, purify, and analyze. Using sound manufacturing practices, a generic will be much the same as the brand name version. But biological drugs are complex mixtures that require a recipe-like manufacturing process. There is batch-to-batch variability even within the same company — but when someone else tries the recipe, the product can turn out quite differently. And purification and analysis of these drugs are much harder. In the absence of tight controls, substandard biosimilars could do considerable damage.”

Monday, February 13, 2012

Home Oxygen Could Raise Burn Risk: Experts

MONDAY, Feb. 13 (HealthDay News) -- Use of home oxygen in the United States has risen over the past decade, which has led to an increase in the number of patients with medical oxygen-related burn injuries, according to experts at the Burn Center at Wake Forest Baptist Medical Center.

"Medical oxygen is 100 percent oxygen. This can raise the oxygen levels inside a structure causing many items that would not normally burn to more easily ignite and burn hotter and faster," Donna Joyner, a registered nurse in Trauma/Burn Outreach, said in a medical center news release.

"Burns resulting from the misuse of home oxygen can be life threatening; however, they are preventable," she added.

Joyner and the U.S. Fire Administration offer the following safety tips for the use of home oxygen:

Never smoke in a home where medical oxygen is in use. "No smoking" signs should be posted inside and outside the home.All ignition sources -- matches, lighters, candles, gas stoves, appliances, electric razors and hair dryers -- should be kept at least 10 feet away from the point where the oxygen comes out.Do not wear oxygen while cooking. Oils, grease and petroleum products can spontaneously ignite when exposed to high levels of oxygen. Also, do not use oil-based lotions, lip balm or aerosol sprays.Homes with medical oxygen must have working smoke alarms that are tested monthly.Keep a fire extinguisher within reach. If a fire occurs, turn off the oxygen and leave the home.Develop a fire escape plan that includes two ways out of every room and an outside meeting place. Practice the escape plan at least twice a year.

More information

The MedlinePlus Medical Encyclopedia has more about medical oxygen safety.

Heart failure patients have new hope

Prevention and treatment options are improving long-term outcomes February 13, 2012 DALLAS, Feb. 13, 2012 — More than six million American adults suffer from heart failure. But, while the prevalence of this disease has increased over time, there are signs that deaths from it have not and hospitalization rates may be stabilizing as well. Healthcare professionals say this is good news and the future looks even more promising. “Despite the increasing number of people affected, the prognosis for patients with heart failure has steadily improved,” said Gregg C. Fonarow, M.D, chairman of American Heart Association Hospital Accreditation Science Committee and professor of cardiovascular medicine of the University of California, Los Angeles. “This is testament in part to better therapies and systems for treating this condition. There has been so much research and advancement in this area that what used to be a very dismal diagnosis is no longer the norm. Used appropriately, available medical and device therapies are even more effective than originally believed and best practices of care have now been shown to save lives.” Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through the heart to meet the body's needs for blood and oxygen. Basically, the heart can't keep up with its workload. The weakened heart can't supply the cells with enough blood. This results in fatigue and shortness of breath. Everyday activities such as walking, climbing stairs or carrying groceries can become difficult. Heart failure is caused by damage to the heart that impairs its ability to function. However, even for the patient with chronic heart muscle weakness, a significant amount of heart function can now be restored by the correct use of heart failure medication and devices. “Even for our patients with advanced disease, there are so many more options now available to us,” said Clyde Yancy, M.D., past president of the American Heart Association and chief of the Division of Cardiology and the Magerstadt Professor at Northwestern University Feinberg School of Medicine in Chicago. “The use of mechanical support such as artificial heart pumping devices, has become remarkable. We can sustain patients long enough to not only allow for heart transplantation but also to serve as definitive therapy and even more provocatively to support recovery of heart muscle function even when seemingly dramatic changes have taken place.” Along with advanced technologies, improvements in quality of care are also making a difference in heart failure outcomes. Studies have shown that heart failure patients treated with American Heart Association/American College of Cardiology guideline-recommended therapies are more likely to survive over the next two years. Every 10 percent improvement in the use of guideline-recommended therapies has been associated with a 13 percent lower risk of death among heart failure patients over the next two years. (Fonarow G, et al. Associations between outpatient heart failure process-of-care measures and mortality. Circulation. 2011;123:1601-1610) Recent studies also show that patients treated in hospitals participating in the American Heart Association’s Get With The Guidelines®-Heart Failure program receive higher quality of care and may experience better outcomes. Hospital readmissions after treatment for heart failure have been a growing and costly issue in the past. But Fonarow said greater use of guideline-recommended therapies, improved care transitions and enhanced participation in quality improvement efforts are key to turning this around. “It’s important for a heart failure patient

Most Teens Who Self-Harm Are Not Evaluated for Mental Health in ER

FRIDAY, Feb. 10 (HealthDay News) -- Most children and teens who deliberately injure themselves are discharged from emergency rooms without an evaluation of their mental health, a new study shows.

The findings are worrisome since risk for suicide is greatest right after an episode of deliberate self-harm, according to researchers at Nationwide Children's Hospital in Columbus, Ohio.

The researchers also found the majority of these kids do not receive any follow-up care with a mental health professional up to one month after their ER visit.

"Emergency department personnel can play a unique role in suicide prevention by assessing the mental health of patients after deliberate self-harm and providing potentially lifesaving referrals for outpatient mental health care," said lead study author Jeff Bridge, principal investigator at the hospital's Center for Innovation in Pediatric Practice, in a news release. "However, the coordination between emergency services for patients who deliberately harm themselves and linkage with outpatient mental health treatment is often inadequate."

For the study in the Journal of the American Academy of Child & Adolescent Psychiatry, researchers examined Medicaid data for adolescents aged 10 to 19 years. Only 39 percent of the patients discharged after trying to harm themselves received a mental health assessment in the emergency department.

Only about half of the children who had visited the ER for a mental health-related reason within the previous 60 days received a mental health evaluation during their visit to the ER for self-harm.

Up to 90 percent of young people who deliberately harm themselves meet criteria for at least one psychiatric disorder, particularly mood disorders, the researchers said.

The U.K.'s National Institute for Health and Clinical Excellence recommends that people who show up in an emergency room for self-harm should receive a mental health evaluation before being released from the hospital.

"This study highlights the need for strategies to promote emergency department mental health assessments, strengthening the training of physicians in pediatric mental health and adolescent suicide prevention and timely transitions to outpatient mental health care," Bridge said.

More information

The American Academy of Child & Adolescent Psychiatry has more about self-injury among teens.

Study Weighs Pros, Cons of Home or Hospital Birth

FRIDAY, Feb. 10 (HealthDay News) -- Babies whose mothers choose to deliver at home are at higher risk of complications after birth, including low Apgar scores and seizures, a new study finds.

However, if the home birth was attended by a certified nurse midwife, some of the added risk disappeared.

But only about 26 percent of home births were attended by a certified nurse midwife, according to a new study to be presented Friday at the Maternal-Fetal Medicine Society's annual meeting in Dallas.

"We observed a higher risk of lower Apgar scores and incidence of neonatal seizures in women who had home births," said study author Dr. Yvonne Cheng, an obstetrician/gynecologist at the University of California, San Francisco. "These adverse findings are particularly present when the birth attendant is not a certified nurse midwife."

She added: "The location of birth is important, but who is present at the delivery is more important."

Cheng and her colleagues analyzed birth certificate data on nearly 2.3 million singleton births in 2008 in the United States. About 10,700 women, or less than 1 percent (0.47 percent), delivered in a birthing center, usually a standalone facility staffed by a midwife and in close proximity to a hospital in case of emergency.

About 12,400 women (0.54 percent) gave birth at home intentionally.

The birth certificates included whether it was a doctor, a certified nurse midwife, an "other midwife" or someone else who assisted with the delivery.

There was little difference in outcomes for babies if they were born in a hospital or a birthing center.

The study did find that babies born at home or a birthing center were much less likely to be delivered via Cesarean section; however, researchers said their data are likely not reliable. The reason is that if a mother intended to give birth at home or in a birthing center but ended up being taken to the hospital for a C-section because of complications, the birth certificate would have recorded an in-hospital birth.

Babies born at home were more than twice as likely to have an Apgar score of under 7 as children born in a hospital or at a birthing center, and also had double the chances of having a seizure.

The Apgar score is a test used to measure a child's skin color, pulse and overall vigor in the moments after birth.

The overall number of kids who had seizures was low -- less than 1 percent at any location.

Prior research has shown that babies with lower Apgar scores are more likely to have complications after birth, such as needing breathing assistance, going to the ICU, having seizures or having developmental issues, Cheng said.

Although the numbers are still small, a growing number of women are choosing to give birth outside of hospitals, Cheng said, with the numbers rising about 20 percent between 2004 and 2008.

Those women often want to give birth without painkillers such as epidurals. They want to have "more control" over the birth experience; may feel more comfortable in their own surroundings; or may want to have multiple people in the room when they deliver, something many hospitals limit, added Dr. Mary Norton, director of perinatal research at Stanford University Medical Center.

Yet, women who are choosing home birth should recognize there are risks, Norton said.

"Even in a normal-health woman with a normal pregnancy, there will always be unanticipated things that can happen and unanticipated emergencies," she said.

At home, you are further from medical care. Whereas birthing centers often have systems in place to transfer a woman to a hospital in case of emergency, women at home may have to wait longer for an ambulance, or it may be difficult to move a woman who is in labor onto a gurney and transport her to a hospital.

"This data does indicate there is a higher level of risk to the baby when delivering at home. If someone is carefully monitored, is in close proximity to the hospital and willing to go to the hospital if needed, then the risks are lower," she said.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

Nemours has more about birthing centers and hospital births.

Emergency Medical Services Education in Emergency Medicine Residency Programs: A National Survey

 2 to 4 weeks). Most programs involve residents on EMS rotations strictly as in‐field observers (63%), some as in‐field providers (20%), and the rest with some combination of the two roles. Ground ride‐along is required in 94% of programs, while air ride‐along is mandatory in 4% and optional in 81% of programs. Direct medical oversight (DMO) certification is required in 41% of residency programs, but not available in 26% of program jurisdictions. Residents in 92% of programs provide DMO. In those programs, most residents (77%) provide DMO primarily while working in the emergency department (ED), 13% during dedicated EMS or medical oversight shifts, and 4% during a combination of these shifts. Disaster‐preparedness was most frequently listed as the component programs would like to add to their EMS curricula.

Conclusions:  There is a wide range in the didactic, online, and in‐field EMS educational experiences provided as part of EM training. Most residents participate in ground ride‐along activities, provide DMO, and have a dedicated EMS rotation. Disaster‐preparedness is the most common desired addition to existing EMS rotations.

ACADEMIC EMERGENCY MEDICINE 2012; 19:1–6 © 2012 by the Society for Academic Emergency Medicine

View Full Article with Supporting Information (HTML) Get PDF (221K)

Injury characteristics and Outcome of Road traffic crash victims at Bugando Medical Centre in Northwestern Tanzania

Sunday, February 12, 2012

New anti-clotting drug fails to meet expectations in major trial

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18480 - EMBARGOED 8AM ET November 13, 2011 Study Highlights:Vorapaxar, a new anti-platelet drug, failed to reduce patients’ odds of experiencing adverse outcomes after treatment for unstable angina or a heart attack due to a partial artery blockage.Patients on vorapaxar had an increased risk of bleeding.ORLANDO, FLA., Nov. 13, 2011 — An experimental clot-inhibiting drug didn’t improve outcomes for patients who experienced a sudden, dangerous reduction of blood flow to the heart, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2011. The study is simultaneously published in the New England Journal of Medicine. In the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) Study, researchers compared vorapaxar to a placebo in patients with non-ST-segment elevation acute coronary syndrome. These patients experience unstable angina or a non-STEMI heart attack, where a coronary artery is partially blocked, reducing blood flow to the heart. Researchers enrolled 12,944 patients at 818 sites in 37 countries. All patients received the usual medical care for their condition, typically involving aspirin and clopidogrel (Plavix), as well as procedures such as catheterization, coronary stenting or surgery if indicated. Half the participants also were given a 40-milligram initial dose followed by a 2.5-milligram daily dose of vorapaxar, the first in a new class of anti-platelet drugs, PAR-1 antagonists. The rest of the patients received a placebo. Participants given vorapaxar were just as likely as those given placebo to experience at least one of five outcomes — cardiovascular-related death, heart attack, stroke, a new hospitalization for unstable angina or urgent revascularization. After two years of study, almost one in five patients in each group had such an outcome (18.5 percent vorapaxar vs. 19.9 percent placebo). Researchers also found that the patients who received vorapaxar had more bleeding and had a three-fold increase in the risk of hemorrhagic stroke. Patients on vorapaxar also had a 14.7 percent risk of cardiovascular death, heart attack or stroke, compared to 16 percent for patients given the placebo, a difference that was not statistically significant. Researchers said there was discordance between these findings and their earlier Phase 2 study. “The difference in the primary endpoint was more modest and the bleeding risk was higher than expected,” said Kenneth W. Mahaffey, M.D., lead author of the study and co-director of cardiovascular research at the Duke Clinical Research Institute in Durham, N.C. “Earlier studies of vorapaxar had not identified an excess bleeding risk, so these findings are surprising. More work is needed to understand the bleeding risk. Whether it’s related to the use of aspirin and clopidogrel in these patients or other factors need to be and will be examined carefully.” “We were surprised and disappointed that TRA•CER failed to meet its primary endpoint,” said Robert Harrington, M.D., chair of the TRA•CER steering committee and director of the Duke Clinical Research Institute. “The lower incidence of cardiovascular death, heart attack or stroke with vorapaxar while not significant, is promising and we look forward to seeing the data from the next trial (TRA 2P TIMI 50) to better understand if or how to proceed with further development of vorapaxar.” Co-authors are Pierluigi Tricoci, M.D., Ph.D.; Yuliya Lokhnygina, Ph.D.; Paul W. Armstrong, M.D.; Phillip E. Aylward, M.D.; Edmond Chen, M.D.; Claes Held, M.D., Ph.D.; Sergio Leonardi, M.D., M.H.S.; Ann Kilian; David J. Moliterno, M.D.; Tyrus L. Rorick, R.N.; John Strony, M.D.; Frans Van de Werf, M.D.; Lars Wallentin, M.D., Ph.D.; Harvey D. White, D.Sc.; and Robert A. Harrington, M.D., for the TRA•CER Steering Committee and TRA•CER investigators. Disclosures are here: http://newsroom.heart.org/pr/aha/document/Disclosures_for_LBCT.xlsx. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., funded the study. ### Statements and conclusions of study authors published in American Heart Association scientific meetings or presentations are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content.  Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding. MEDIA CONTACTS:AHA News Media in Dallas: (214) 706-1396AHA News Media Office, Nov. 12–16, at theOrange County Convention Center: (407) 685-5410For public inquiries: (800) AHA-USA1 (242-8721) Tweet Newsroom Home Browse News Releases Browse Multimedia Audio Images Podcasts Video & Animations Usage Policy News Media Media Contacts Access to AHA/ASA Embargoed Media Materials Boilerplate Branding Guidelines Copyright Permissions Embargo Policy Linking Policy Public Service Announcements Frequently Requested Resources About Us Heart and Stroke Encyclopedia Medical Illustration Library (For viewing only

Breastfeeding absolutely vital for strengthening the developing lungs of children, research finds

Just released: Spirulina and Chlorella tablets infused with functional herbs: Ashwangandha, Bacopa, Ginkgo, Mucuna, Tribulus, Turmeric and many more! Click here to see the varieties on our store specials page (scroll down below the Nascent Iodine).--

Eating less made easier


Recently, we applauded the New York City Health Department’s latest campaign to warn the public about increasing portion sizes. Now a new study published in the journal Health Affairs has added to the mounting evidence that offering smaller portions at restaurants may be an effective means of reducing caloric intake.

For their study, researchers from Tulane University examined the ordering choices of patrons visiting a Chinese fast food restaurant located on a college campus. In a trio of small studies, the results demonstrated that offering smaller portion sizes more effectively encouraged moderation than the practice of posting calorie counts. In fact, almost one-third of customers opted for the smaller portion sizes — which contained 200 fewer calories — when these portions were offered at a 25-cent discounted rate.

“Hopefully, restaurants will take this study to heart and offer consumers the choice of smaller portions,” says ACSH’s Dr. Ruth Kava. “Such an option could really help people who frequently eat out yet still try to control their calorie intake.”

“This study supports the idea that, even with relatively small incentives,” says ACSH's Dr. Gilbert Ross, “people will accept smaller portion sizes. Given that this strategy appears to be a more effective way to reduce caloric intake, we encourage more restaurants to offer these smaller plate options.”

Some salient facts about salt


What’s the largest source of salt in our diets? Is it potato chips? French fries? Neither of these, says a recent report form the U.S. Centers for Disease Control and Prevention (CDC). Actually, bread and rolls provide us with the greatest amount of salt in our diets.

This answer may come as a surprise to many Americans who are used to being told to avoid snacks like chips and pretzels because of their high sodium content. But these snacks were actually at the bottom of the CDC’s list of the top 10 sources of sodium in the American diet. The top five sources, on the other hand, were bread and rolls, cured meats and cold cuts, pizza, poultry, and soups. The CDC collected this data through surveys of over 7,000 people in 2007 and 2008, including almost 3,000 children. Researchers obtained detailed information about what the participants ate, then categorized these responses and assigned sodium levels to each category.

“This is just another part of nutrition that people need to be aware of,” says ACSH’s Cheryl Martin. “Most of us don’t know how much sodium is in the products we consume on a daily basis.” Indeed, while the CDC does not necessarily recommend that people cut down on bread and rolls, they are advising consumers to be mindful of sodium content and to read labels, since the results of the agency’s study show that the greatest amount of sodium we consume may come from sources we don’t expect.

ACSH's Dr. Ruth Kava comments, “People have been told before that most of their salt does not come from the salt shaker, but that it’s already present in the foods they buy. This report is just further evidence that there are many sources of salt in our diets that may not be obvious.”

But ACSH’s Dr. Elizabeth Whelan reminds us that, while it’s important to be mindful of nutrition labels, “most of us do not need to be concerned with following a very low-sodium diet. This type of diet has not been shown to help many people; in some cases, it can actually be detrimental.”

Prehospital trauma care reduces mortality. Ten-year results from a time-cohort and trauma audit study in Iraq

Two anti-clotting regimens similarly effective in patients undergoing angioplasty after heart attack

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18569 - EMBARGOED until 8am ET November 13, 2011 Study Highlights:Two anti-clotting treatments

Musculoskeletal fracture: what is different in children?—skimboarding, fall, right foot pain

Injury characteristics and Outcome of Road traffic crash victims at Bugando Medical Centre in Northwestern Tanzania

Platelet inhibitor helps heart attack patients whether given via peripheral vein or directly into blocked coronary artery

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18633 - EMBARGOED UNTIL 8AM ET November 13, 2011 Study Highlights:The platelet inhibitor abciximab was no more effective in reducing death in STEMI heart attack patients when it was delivered directly into the blocked coronary artery than when it was given intravenously.Intracoronary delivery of the drug was safe and might help prevent development of heart failure, researchers said. ORLANDO, FLA., Nov. 13, 2011 — Administering a platelet inhibitor directly into a blocked coronary artery was no more effective than intravenous delivery in improving overall health outcomes in severe heart attack patients, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2011. In the Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention (AIDA STEMI) Trial, researchers tested whether administering a dose of the anti-platelet agent abciximab into the blocked coronary artery (intracoronary) route, instead of the standard intravenous route, would improve outcomes for patients undergoing percutaneous coronary intervention (PCI). Patients in the study had suffered an ST-elevation myocardial infarction, or STEMI, a heart attack caused by a complete blockage of blood flow to the heart.Researchers randomized 2,065 STEMI patients undergoing PCI (which usually includes angioplasty with stenting) at 22 hospitals from July 2008 to April 2011 to receive abciximab by an IV infusion or directly into the blocked artery. Within 90 days, 7 percent of those receiving the direct administration died, had another heart attack or developed new heart failure, compared to 7.6 percent of those receiving the intraveneous route. “Neither therapy arm was superior to the other in the primary endpoint,” said Holger Thiele, M.D., lead researcher of the study and deputy director of the Department of Internal Medicine/Cardiology at the University of Leipzig – Heart Center in Germany. “However, we found a lower rate of heart failure in the intracoronary patients.” Only 2.4 percent (22 of 935) patients receiving the intracoronary dose were diagnosed with heart failure within 90 days, compared to 4.1 percent, or 38 of the 932 patients, receiving the intraveneous dose, (P

Sugar-sweetened beverages may increase cardiovascular risk in women

Abstract: 8438 - EMBARGOED UNTIL 11AM ET November 13, 2011 Study Highlights:  Listen to PodcastWomen who drank two or more sugar-sweetened beverages daily experienced increasing waist circumferences, developed high triglycerides, and a high risk for type 2 diabetes. Women may have a greater chance for developing cardiovascular disease risk factors from sugar-sweetened drinks because they require fewer calories than  men.ORLANDO, FLA., Nov. 13, 2011 — Drinking two or more sugar-sweetened beverages a day may expand a woman’s waistline and increase her risk of heart disease and diabetes, according to research presented at the American Heart Association’s Scientific Sessions 2011. In this study, researchers compared middle-aged and older women who drank two or more sugar-sweetened beverages a day, such as carbonated sodas or flavored waters with added sugar, to women who drank one or less daily. Women consuming two or more beverages per day were nearly four times as likely to develop high triglycerides, and were significantly more likely to increase their waist sizes and to develop impaired fasting glucose levels. The same associations were not observed in men. “Women who drank more than two sugar-sweetened drinks a day had increasing waist sizes, but weren’t necessarily gaining weight,” said Christina Shay, Ph.D., lead author of the study and assistant professor at the University of Oklahoma Health Sciences Center in Oklahoma City. “These women also developed high triglycerides and women with normal blood glucose levels more frequently went from having a low risk to a high risk of developing diabetes over time.” The Multi-Ethnic Study of Atherosclerosis (MESA) included food frequency surveys in 4,166 African-American, Caucasian, Chinese-Americans and Hispanic adults 45 to 84 years old. At the beginning of the study the participants didn’t have cardiovascular disease. Researchers assessed risk factors in three follow-up exams spanning five years starting in 2002. Participants were monitored for weight gain, increases in waist circumference, low levels of high density lipoproteins (HDL “good” cholesterol), high levels of low density lipoproteins (LDL “bad” cholesterol), high triglycerides, impaired fasting glucose levels, and type 2 diabetes. “Most people assume that individuals who consume a lot of sugar-sweetened drinks have an increase in obesity, which in turn, increases their risk for heart disease and diabetes,” said Shay, formerly of Northwestern University’s Department of Preventive Medicine in Chicago, where the study was conducted. “Although this does occur, this study showed that risk factors for heart disease and stroke developed even when the women didn’t gain weight.” Women may have a greater chance for developing cardiovascular disease risk factors from sugar-sweetened drinks because they require fewer calories than men which makes each calorie count more towards cardiovascular risk in women, Shay said. Researchers have yet to determine exactly how sugar-sweetened beverages influence cardiovascular risk factors such as high triglycerides in individuals who do not gain weight, Shay said, but further work is planned to try and figure that out. Co-authors include Jennifer A. Nettleton, Ph.D.; Pamela L. Lutsey, Ph.D., M.P.H.; Tamar S. Polonsky, M.D.; Mercedes R. Carnethon, Ph.D.; Cheeling Chan, M.S.; Linda Van Horn, Ph.D., R.D.; and Gregory Burke, M.D. Author disclosures are on the abstract. The National Heart, Lung, and Blood Institute funded the study.  ### Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.  The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content.  Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding. NR11-1132 (SS11/Shay) Note: Actual presentation is 2:30 p.m. ET, Wednesday, Nov. 16. NEW for Scientific Sessions 2011: All downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release linkhttp://newsroom.heart.org/pr/aha/_prv-sugar-sweetened-beverages-may-217750.aspx, along with general Sessions multimedia resources. Video clips with researchers/authors of studies will be added to the release links after embargo. Follow news from AHA Scientific Sessions 2011 via Twitter:  http://twitter.com/#!/heartnews . Follow #AHANews2011. For Media Inquiries:AHA News Media in Dallas: (214) 706-1396AHA News Media Office, Nov. 12-16at the Orange County Convention Center: (407) 685-5410For Public Inquiries:  (800)-AHA-USA1 (242-8721) Tweet Newsroom Home Browse News Releases Browse Multimedia Audio Images Podcasts Video & Animations Usage Policy News Media Media Contacts Access to AHA/ASA Embargoed Media Materials Boilerplate Branding Guidelines Copyright Permissions Embargo Policy Linking Policy Public Service Announcements Frequently Requested Resources About Us Heart and Stroke Encyclopedia Medical Illustration Library (For viewing only

Elective angioplasty patients can fare well in experienced hospitals with no heart surgery capabilities

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18558 - EMBARGOED UNTIL 8AM ET November 14, 2011 Study Highlights:Patients who had non-emergency artery-opening angioplasty or stent implantation at hospitals without heart surgery capabilities fared as well as those in hospitals that did.Both groups of patients had less than a 1 percent death rate.ORLANDO, FLA., Nov. 14, 2011

Custom consent forms help patients better understand heart procedures

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18588 - EMBARGOED UNTIL 8AM ET November 14, 2011 Study Highlights:An easy-to-understand consent form with pictures and personalized information helped patients understand angioplasty and stent procedures.The web-based form allows doctors to input patients’ individual risk factors and puts patients at ease more than traditional forms.ORLANDO, FLA., Nov. 14, 2011

Consultation with pharmacists didn’t reduce heart failure death rates or hospitalizations

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18568 - EMBARGOED UNTIL 8AM ET November 14, 2011 Study Highlights:The rate of death and hospitalization for community-based heart failure patients remained the same whether or not they had specific consultation with a pharmacist collaborating with a physician.Pharmacist involvement increased the number of patients given recommended heart failure drugs, but levels of some treatments were already good at baseline.ORLANDO, FLA., Nov. 14, 2011

Free heart meds reduce heart attacks, heart failure but not revascularization rates

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18638 - EMBARGOED UNTIL 8AM November 14, 2011 Study Highlights:Compared to patients who had prescription co-pays, heart attack patients whose insurance company picked up the entire tab for their heart medications had fewer subsequent heart attacks and heart failure, but no reduction in the rate of revascularization to reopen clogged arteries.Patients who got the free medications were more likely to take their medicine as prescribed.Free medicine saved patients money while not increasing overall healthcare costs.ORLANDO, FLA., Nov. 14, 2011

Heart rhythm drug increases risk of death for some patients in halted study

American Heart Association Late-Breaking Meeting Report - Abstract: 19068 - EMBARGOED UNTIL 12:30PM ET November 14, 2011 Study Highlights:Dronedarone, a drug used to treat people with intermittent atrial fibrillation, doubled the risk of death and serious cardiovascular disorders in a study of patients with permanent AF.Because of these early findings, researchers ended the study with only 30 percent of the 10,800 intended patients enrolled.ORLANDO, FLA., Nov. 14, 2011 — A drug used successfully to treat people with intermittent atrial fibrillation, an abnormal heart rhythm, was unexpectedly dangerous for some patients with a permanent form of the condition, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2011.The study is simultaneously published in the New England Journal of Medicine. Atrial fibrillation (AF), which occurs when the two upper heart chambers beat erratically, affects about 2.7 million Americans. The heart may return to normal rhythm on its own in some people with intermittent or non-permanent AF.  For those with permanent AF, it does not. Permanent AF is usually managed with heart rate-controlling medications.Dronedarone is an anti-arrhythmic drug used for patients with non-permanent AF to reduce AF recurrence and to lower the chances of being hospitalized for heart problems. It is not approved for permanent AF. “No previous trials have investigated interventions to reduce morbidity and mortality in patients with permanent AF, a high-risk population,” said Stuart J. Connolly, M.D., lead author of the study and professor of cardiology at McMaster University in Hamilton, Ontario, Canada. In July, researchers stopped enrollment into a randomized clinical trial of dronedarone in patients with permanent AF when their data and safety monitoring board detected excessive serious vascular events and deaths in the drug-treated patients. PALLAS (Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy) included only 3,236 of the planned 10,800 patients before researchers stopped recruiting and treatment. “The message is that the drug dronedarone should not be used for permanent atrial fibrillation,” Connolly said. PALLAS patients, all 65 years or older with permanent AF and other risk factors for vascular events, were randomized to either dronedarone or placebo. Among the findings reported: Overall risk of major vascular events such as stroke, heart attack or death from cardiovascular causes was 2.2 times greater on dronedarone than on placebo: 43 dronedarone patients and 19 on placebo suffered a stroke, heart attack, systemic blood clot or cardiovascular death.Twenty-one cardiovascular deaths occurred among dronedarone patients and 10 in the placebo arm.Thirteen arrhythmia deaths occurred in the drug group and four in the control group.Twenty-two treated patients had strokes — 2.5 times more than the nine strokes in people on placebo.Dronedarone increased the risk of heart failure hospitalization.Dronedarone patients taking the heart rhythm drug digitalis before accrual — almost one-third of those treated — had a 36 percent increase in their digitalis blood levels.“There is evidence that this increase in digitalis played a causative role in the increased risk of cardiovascular death,” Connolly said. “But this does not explain the increase in stroke or heart failure.” Disclosures are here: http://newsroom.heart.org/pr/aha/document/Disclosures_for_LBCT.xlsx.Sanofi-Aventis funded the study. ### Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding. CONTACT:AHA News Media in Dallas: (214) 706-1396AHA News Media Office, Nov. 12–16, at theOrange County Convention Center: (407) 685-5410For public inquiries: (800) AHA-USA1 (242-8721) Tweet Newsroom Home Browse News Releases Browse Multimedia Audio Images Podcasts Video & Animations Usage Policy News Media Media Contacts Access to AHA/ASA Embargoed Media Materials Boilerplate Branding Guidelines Copyright Permissions Embargo Policy Linking Policy Public Service Announcements Frequently Requested Resources About Us Heart and Stroke Encyclopedia Medical Illustration Library (For viewing only

Catheter ablation worked better than drugs for periodic atrial fibrillation

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18473 - EMBARGOED UNTIL 12:30PM ET November 14, 2011 Study Highlights:High frequency radio waves that destroy electrical triggers in the heart (a treatment called radiofrequency ablation) worked as well as or better than drugs to treat patients with periodic erratic heartbeats.Episodes of erratic heartbeats in the heart’s upper chambers, called paroxysmal atrial fibrillation, were less frequent in patients who underwent the ablation procedure.ORLANDO, FLA., Nov. 14, 2011 —  Catheter ablation, which uses high frequency radio waves to destroy electrical triggers in the heart, worked as well as or better than drugs to reduce periodic episodes of erratic heartbeats in patients with atrial fibrillation, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2011. Atrial fibrillation (AF) occurs when the heart’s two upper chambers beat erratically. In one form of the condition, paroxysmal AF, patients have bouts of erratic beats that begin spontaneously and usually last less than a week. Anti-arrhythmic medications can control the heart rhythm and symptoms of AF, but many patients don’t respond well. Atrial fibrillation can lead to serious adverse events such as clots travelling from the heart to obstruct arteries supplying the brain (causing strokes) or other parts of the body causing tissue damage. Another option for stabilizing the heartbeat is delivering high frequency alternating current through a catheter to destroy the small bits of heart tissue that cause AF. In this case, researchers targeted tissue surrounding the pulmonary veins. This treatment option has not previously been tested for patients who haven’t tried drug treatment.Researchers randomized participants to either radiofrequency ablation (146) or an anti-arrhythmic drug (148). They assessed the patients at the study’s start, and at 3, 6, 12, 18 and 24 months. Each time, patients wore a portable heart monitor for seven days. Significant findings included:At 3, 6, 12 and 18 months, there was no significant difference in the amount of time patients in the two groups experienced AF (AF burden) nor in the cumulative AF burden.At 24 months, the ablation group did have significantly less AF burden than the drug-treated patients.Twenty-two radiofrequency ablation patients (15 percent) had AF compared to 43 (29 percent) treated with drugs.Ten ablation patients (7 percent) had symptomatic AF episodes compared to 24 (16 percent) in the drug group.“Ablation therapy is at least as good and tends to be better than drug therapy at preventing episodes of atrial fibrillation,” said Jens Cosedis Nielsen, M.D., lead researcher and professor of cardiology at Aarhus University Hospital in Denmark. Of the patients primarily treated with ablation, 13 needed supplementary drugs and 54 patients who didn’t improve with drugs underwent supplementary radiofrequency ablation.“Not every patient should be offered ablation, but this research should be discussed with patients when a physician feels it is a viable treatment option,” Nielsen said.      Co-authors are Arne Johannesen, M.D., D.M.Sci.; Pekka Raatikainen, M.D.; Gerhard Hindricks, M.D.; Håkan Walfridsson, M.D.; Ole Kongstad, M.D.; Steen Pehrson, M.D., D.M.Sci.; Anders Englund, M.D.; Juha Hartikainen, M.D.; Leif Spange Mortensen, M.S.; and Peter Steen Hansen, M.D., D.M.Sci.       Disclosures are here: http://newsroom.heart.org/pr/aha/document/Disclosures_for_LBCT.xlsx.      Biosense Webster, Inc., and the Danish Heart Foundation funded the study. ###Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding. CONTACT:AHA News Media in Dallas: (214) 706-1396AHA News Media Office, Nov. 12–16, at theOrange County Convention Center: (407) 685-5410For public inquiries: (800) AHA-USA1 (242-8721)   Tweet Newsroom Home Browse News Releases Browse Multimedia Audio Images Podcasts Video & Animations Usage Policy News Media Media Contacts Access to AHA/ASA Embargoed Media Materials Boilerplate Branding Guidelines Copyright Permissions Embargo Policy Linking Policy Public Service Announcements Frequently Requested Resources About Us Heart and Stroke Encyclopedia Medical Illustration Library (For viewing only

New surgery for atrial fibrillation worked better than standard procedure, but with more complications

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18471 - EMBARGOED UNTIL 12:30 PM ET November 14, 2011 Study Highlights:Minimally invasive surgical ablation was more effective than catheter ablation to treat atrial fibrillation, but was significantly more likely to cause major complications.Complications during the procedure occurred in 23 percent of patients undergoing surgical ablation and in 3.2 percent of the catheter-based ablation group.The surgical procedure is not approved for treating atrial fibrillation in the United States.ORLANDO, FLA., Nov. 14, 2011 — A minimally invasive surgical procedure to treat atrial fibrillation (AF) proved more effective than catheter ablation in two high-risk patient groups but was significantly more likely to result in complications, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2011.The study is simultaneously published in Circulation: Journal of the American Heart Association. In their study, researchers compared the efficacy and safety of video-assisted epicardial surgical ablation to pulmonary vein catheter ablation, an established and less invasive technique. Before catheter ablation was developed in the mid-1990s, AF patients in whom medications didn’t control symptoms could only be treated with surgery that required opening the chest. Researchers enrolled 124 patients, 101 of them men, at two sites — St. Antonius Hospital in Nieuwegein, The Netherlands, and the Hospital Clinic at the University of Barcelona in Spain. The patients had a high risk of failing to gain relief of AF from catheter ablation, either because the procedure hadn’t worked previously (67 percent) or because they had an enlarged atrium (one of the heart’s upper chambers affected by atrial fibrillation). The surgical ablation procedure involves a few small incisions in the chest wall — one for the endoscope (a thin, camera-tipped wire) and the others for surgical tools. The heart continues to beat while the surgeon uses radiofrequency energy to destroy and tissue around the heart that is causing the irregular heartbeats. In catheter ablation, a doctor inserts long, flexible tubes into the blood vessels of the leg and guides the catheter into the atrium. Radiofrequency energy is delivered through the tip of the catheter to destroy the tissue targeted for ablation. Sixty-one patients were randomized to surgical ablation and 63 to catheter ablation; 66 percent had paroxysmal, or sporadic AF, and 34 percent had persistent AF. Results of the study showed:One year after the procedures, 36.5 percent of catheter ablation patients were AF-free without drugs versus 65.6 percent of the surgical ablation group, a meaningful difference that varied little regardless of the type of AF, existing preconditions or where the patient was treated.Major adverse events during the procedure occurred in 23 percent of surgical patients and 3.2 percent of the catheter group, a significant difference.Subsequent adverse events during the one-year follow-up occurred in similar numbers in both groups (12 percent of catheter patients and 11 percent of surgical patients).“The difference between the surgical group and the catheter ablation group was mostly due to more procedural events. A substantial part consisted of collapsed lungs, which could mostly be managed conservatively, several bleeding complications and two pacemakers. Many adverse events were solved without permanent harm to the patients,” said Lucas Boersma, M.D., Ph.D., lead researcher and a cardiologist at St. Antonius. “The risk of the procedure accompanying the chance for greater success needs to be carefully weighed by physicians and patients.”Previous research suggests results would likely apply to both genders and all races and ethnicities, he said. Co-authors are Manuel Castella, M.D., Ph.D.; WimJan van Boven, M.D.; Antonio Berruezo, M.D.; Alaadin Yilmaz, M.D.; Mercedes Nadal, M.D.; E Sandoval, M.D.; Naiara Calvo, M.D.; Josep Brugada, M.D., Ph.D.; Johannes Kelder, M.D.; Maurits Wijffels, M.D., Ph.D.; and Lluís Mont, M.D.; Ph.D.Disclosures are here: http://newsroom.heart.org/pr/aha/document/Disclosures_for_LBCT.xlsx.Participating hospitals and a grant from AtriCure partly funded the study. ###Statements and conclusions of study authors published in American Heart Association scientific meetings or presentations are solely those of the study authors and do not necessarily reflect the association’s policy or position.  The association makes no representation or guarantee as to their accuracy or reliability.  The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content.  Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding CONTACT:AHA News Media in Dallas: (214) 706-1396AHA News Media Office, Nov. 12–16, at theOrange County Convention Center: (407) 685-5410For public inquiries: (800) AHA-USA1 (242-8721) Tweet Newsroom Home Browse News Releases Browse Multimedia Audio Images Podcasts Video & Animations Usage Policy News Media Media Contacts Access to AHA/ASA Embargoed Media Materials Boilerplate Branding Guidelines Copyright Permissions Embargo Policy Linking Policy Public Service Announcements Frequently Requested Resources About Us Heart and Stroke Encyclopedia Medical Illustration Library (For viewing only

Saturday, February 11, 2012

Celivarone doesn’t prevent sudden death, unneeded electrical shocks

American Heart Association Late-Breaking Clinical Trial Report - Abstract: 18631 - EMBARGOED UNTIL 12:30PM ET November 14, 2011 Study Highlights:The experimental drug celivarone didn’t prevent sudden death and unneeded electrical shocks from implantable defibrillators any better than a placebo.Patients taking celivarone had fewer other adverse effects, but the lack of effectiveness makes further trials unlikely.ORLANDO, FLA., Nov. 14, 2011 — An experimental drug for stabilizing irregular heart rhythms wasn’t more effective than placebo in preventing sudden cardiac death and unnecessary firings of implanted defibrillators, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2011.The study is simultaneously published in Circulation: Journal of the American Heart Association. “It’s somewhat disappointing because we thought we had something promising for a very serious problem,” said Peter R. Kowey, M.D., lead author of the study and chief of cardiology at Main Line Health, a Philadelphia-area hospital. “But we are very pleased with the quality of the data.” Implantable cardioverter defibrillators (ICDs) can send electric shocks to the heart to normalize potentially fatal irregular heart rhythms that can cause the heart to stop effectively pumping blood. Many patients also receive amiodarone or sotalol to prevent irregular rhythms, but the drugs aren’t always effective and can have side effects. No drug has gained regulatory approval in the United States for this particular indication. Celivarone is biochemically similar to amiodarone and another heart rhythm drug called dronedarone. Kowey and his colleagues conducted the 486-patient ALPHEE trial after a smaller study of ICD patients called ICARIOS, completed in 2008, suggested celivarone might be beneficial. They successfully enrolled high-risk patients at 151 centers in 26 countries, including 133 patients at 37 U.S. sites. Patients were 64 years old on average. The researchers found no meaningful differences among the high-risk patients randomized to placebo or 50, 100 or 300 mg daily doses of celivarone. A fifth group received amiodarone that was used as a “calibrator” to insure the integrity and interpretability of the trial. Other findings included:No real differences in what triggered ICD responses occurred between the groups.Differences in patients with an appropriate ICD reaction weren’t significant.Six patients died of sudden death, but differences between the groups weren’t significant.Those on amiodarone showed a trend toward fewer unnecessary ICD shocks but a slightly higher death rate.Some benefits of celivarone may have been lost because of the small number of participants in each study group. Women comprised only 11.3 percent and non-whites 7.2 percent, Kowey said. “It is important for people to know about efforts to find the best therapy for ICD patients, even negative studies,” Kowey said. “We believe that publication of negative trials confirms the integrity of the process.” The ALPHEE trial is formally named: Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50, 100 Or 300 Mg OD with Amiodarone as Calibrator for the Prevention of ICD Interventions or Death. The ICARIOS trial was formally named: Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-Triggered Icd interventiOnS.Co-authors are Etienne Aliot, M.D.; Alessandro Capucci, M.D.; Stuart J. Connolly, M.D.; Harry Crijns, M.D.; Stefan H. Hohnloser, M.D.; Piotr Kulakowski, M.D., Ph.D.; David Radzik, M.D.; and Denis Roy, M.D. Disclosures are here: http://newsroom.heart.org/pr/aha/document/Disclosures_for_LBCT.xlsx.Sanofi-Aventis funded the study.### Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.  The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content.  Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding. CONTACT:AHA News Media in Dallas: (214) 706-1396AHA News Media Office, Nov. 12–16, at theOrange County Convention Center: (407) 685-5410For public inquiries: (800) AHA-USA1 (242-8721)   Tweet Newsroom Home Browse News Releases Browse Multimedia Audio Images Podcasts Video & Animations Usage Policy News Media Media Contacts Access to AHA/ASA Embargoed Media Materials Boilerplate Branding Guidelines Copyright Permissions Embargo Policy Linking Policy Public Service Announcements Frequently Requested Resources About Us Heart and Stroke Encyclopedia Medical Illustration Library (For viewing only

American Heart Association and Wiley-Blackwell Launch Open Access Journal for Heart Disease and Stroke

November 14, 2011 Dallas, Nov. 15, 2011 – The American Heart Association (AHA) and Wiley-Blackwell, the scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, Inc., today announced an innovative venture to publish a new open access journal, Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, which will launch this fall. Journal of the American Heart Association will serve as the first online-only open access journal for the AHA, and joins the AHA’s prestigious portfolio of 11 peer-reviewed print and online subscription-based scientific journals, including Circulation; Stroke; Arteriosclerosis, Thrombosis, and Vascular Biology; Circulation Research; and Hypertension. Journal of the American Heart Association will provide rapid publication based on rigorous peer review, aiming for three weeks from acceptance to online publication. The journal will enable authors to be fully compliant with open access requirements of funding organizations and institutions where they apply. All articles will be freely available on HighWire, the journal’s ePublishing platform, and deposited in PubMed Central immediately upon publication. Vickie Thaw, Publisher at Wiley-Blackwell for Journal of the American Heart Association commented, “We are very enthusiastic about our new partnership with AHA to which Wiley-Blackwell brings a strong history of innovation in journal publishing and extensive global reach. We are looking forward to helping the AHA to develop Journal of the American Heart Association into a successful, high quality journal.” The AHA has appointed Dr. Joseph Vita as Editor in Chief of Journal of the American Heart Association. Dr. Vita is Professor of Medicine at Boston University School of Medicine and Associate Chief of Cardiology for Academic Affairs at Boston Medical Center. He is the current Deputy Editor of the AHA journal Circulation, an active contributor on numerous study sections for the NIH and AHA, and Supervisor of a translational research program in vascular biology. “Launching JAHA, our new journal, is an exciting and pivotal moment for the AHA because we will now be able to offer researchers our first open access alternative, and it will perfectly complete and complement our existing set of journals.  We are energized by the opportunities that our partnership with Wiley-Blackwell offers, such as their devotion to their society partners, and their marketing ideas and reach,” said Martha Cathcart, PhD, the Scientific Publishing Committee chair for the American Heart Association. Dr. Vita comments, “Journal of the American Heart Association will provide a global publishing forum for basic and clinical research articles, reviews, and special reports on cardiovascular disease and stroke. Our content will be rapidly and widely accessible, accelerating the translation of strong science into effective practice.” ### About the American Heart AssociationThe American Heart Association is devoted to saving people from heart disease and stroke – America’s No. 1 and No. 4 killers. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or join us, call 1-800-AHA-USA1 or any of our offices around the country, or visit www.heart.org. About WileyFounded in 1807, John Wiley & Sons, Inc., has been a valued source of information and understanding for more than 200 years.  Wiley's global headquarters are located in Hoboken, NJ, with operations in the US, Europe, Asia, Canada and Australia, see www.wiley.com. Wiley-Blackwell is the international scientific medical, technical and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley-Blackwell publishes 1,500 peer-reviewed journals and 1,500